Bringing surface plasmon resonance technology to drug discovery labs

In the pharmaceutical drug discovery field, determining how cells and biomolecules interact with each other is key to how well a drug works. A drug that efficiently binds to the appropriate location on or in a cell has a greater chance of being an effective medicine. Surface plasmon resonance (SPR) technology is an invaluable tool during this kind of research.

SPR uses light to provide a non-invasive, label-free way of observing binding interactions in real time. With SPR, scientists can learn more about the mechanics of biomolecular interaction. This information is then used to improve the binding properties of a drug – in other words, to improve a drug’s performance.

SPR is also a powerful tool in cancer research. In this field, the technique is not only used to develop drugs to fight disease, but is also used to study how cells and biomolecules interact with each other. Cancer is often characterized by rampant cell division, and SPR is being used to investigate the molecular basis for this phenomenon.

Until now, however, researchers have often been dependent on core facilities and centralized labs for access to SPR technology. With SensiQ’s dual-channel, semi-automated SPR system, this kind of research can be performed in real time, with high quality affinity and kinetic data available to labs of all sizes, in an uncompromised, affordable solution. The SensiQ technology uses advanced microfluidics, proven surface attachment methodologies and state-of-the-art data analysis tools to provide kinetic, affinity and concentration data that researchers can use with confidence.

To learn more about the manufacturer and products related to this article, please visit the following link:

Please contact us and speak to one of our sales representatives to request a quote or more information on any of our products.